AVROBIO Inc. (NASDAQ: AVRO) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “AVROBIO reported 4Q19/FY19 earnings yesterday. 4Q19 EPS was $(0.72) vs. FactSet consensus of $(0.59) and FY19 EPS was $(2.66) vs. FactSet consensus of $(2.50). We do not see earnings as the most important value driver for AVRO at this stage. Importantly, the company has a solid cash position (runway into 2Q22) to weather the current Covid-19 situation, and no major impact on patient enrollment/dosing is expected at the moment, although the situation remains fluid. We highlight important catalysts to look for in 2020 below (Fabry update, R&D Day, registration pathway in Fabry, additional indications).”
To request access to the full report, visit http://nnw.fm/SaZ9d
About AVROBIO Inc.
Our mission is to free people from a lifetime of genetic disease with a single dose of gene therapy. We aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone. Our clinical-stage programs include Fabry disease, Gaucher disease and cystinosis and we also are advancing a program in Pompe disease. AVROBIO is powered by the plato™ gene therapy platform, our foundation designed to scale gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario. For additional information, visit www.avrobio.com
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
